Comets want to be mentally prepared for Nevada

Posted on by

WEST LIBERTY, Iowa They've been through the physical training all season long.

Now, the West Liberty High School volleyball team wants to make sure that it's mentally ready for Wednesday morning's Class 3A state quarterfinal against Nevada at the U.S. Cellular Center in Cedar Rapids.

The Cubs (37-9) will face West Liberty (36-5) at 10 a.m. on Court Two.

"We need to get our minds ready," Comets senior Kayla Kaalberg said. "We know that we have to execute, be self-disciplined and know that every day we have a team we can trust behind our backs on the court."

The dossier on West Liberty's opponent is very similar to other opponents the Comets have faced.

The Cubs will have a height advantage, led by 6-foot junior Kati Cassabaum, who is averaging 3.12 kills per set and has accumulated 109 blocks, the third-most of any 3A state-qualifying player.

This is nothing new for West Liberty, who has no player on the roster taller than 5-foot-9. The Comets have instead found ways to play above their height, showing success in that area as recently as last Tuesday's regional final against Mediapolis.

"Our blockers have helped a lot," West Liberty's Summer Kopet said. "When we played Mepo, they had big hitters and our blockers helped make it easier for us on the back row.

"We don't have that tall of girls ... but even getting a touch [on the ball] helps."

Kopet, a senior, is one of five players averaging two or more digs per set on West Liberty's roster, which has helped make the Comets a tough team to score on.

More:

Comets want to be mentally prepared for Nevada

Comets heading to state finals

Posted on by

EMMAUS Ashleigh Thomas moment came midway in the second half.

The junior was in open field with only the goalkeeper standing in her way. As Oley Valley defenders chased her down from behind, the junior was able to get off a shot. It went wide and high.

The missed opportunity stung, so when Thomas collected a rebound off the keepers pad on a penalty corner, there was no way that ball wasnt going to find the back of the cage.

It was a little disappointing working it all the way up, Thomas said. I got so psyched. To mess it up right at five yards was kind of upsetting. It just gave me that much more drive to work together with my team and try to get that goal back.

Thomas redemptive goal gave the Comets (23-0-1) the breathing room it needed and paved the way to a 3-0 win over Oley Valley in the semifinals of the PIAA Class 2A Field Hockey Championships at Emmaus H.S. Tuesday night.

The win sends Crestwood into the finals for the third straight year. They will face Villa Maria, the No. 1 seed from District 1 and 3-0 winners over Moravian Academy. The championship game is slated for noon on Saturday at Zephyr Sports Complex in Whitehall.

Im so excited, Thomas said. Even if we make it to the same point, it still gives you that excited feeling. Im so excited.

After a sluggish start in their quarterfinals matchup against Selinsgrove, the Comets came out with much more energy.

Crestwoods first goal came at 6:06 in the first half on a busted penalty corner. Jordan Olenginski took advantage of a feed from Sarah Macko to put the Comets on the board.

From there, it was all about the Crestwood defense. Cara Jarmiolowski made a strong defensive stop on the goal line early in the second half, while Katie Karpinski and Lauren Rowski help to hold an Oley Valley offense that scored 105 goals this season scoreless. The Lynx finished with five shots on goal and four penalty corners, in comparison to Crestwoods 11 shots on goal and nine penalty corners.

More here:

Comets heading to state finals

Amgen Reveals Positive Data For Brodalumab In Patients With Plaque Psoriasis

Posted on by

By RTT News, November 11, 2014, 04:14:00 PM EDT

(RTTNews.com) - Amgen ( AMGN ) and AstraZeneca ( AZN ) Tuesday announced that AMAGINE-3, a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints when compared with both Stelara (ustekinumab) and placebo at week 12.

In the trial, Brodalumab was shown to be superior to Stelara on the primary endpoint of achieving total clearance of skin disease, as measured by the Psoriasis Area Severity Index (PASI 100).

When compared with placebo, a significantly greater proportion of patients treated with brodalumab achieved at least a 75 percent improvement from baseline in disease severity at week 12, as measured by the Psoriasis Area Severity Index (PASI 75).

A significantly greater proportion of patients treated with brodalumab also achieved clear or almost clear skin at week 12 compared with placebo, according to the static Physician Global Assessment (sPGA 0 or 1). All key secondary endpoints comparing brodalumab with Stelara and placebo were also met.

Results showed that 36.7 percent of patients in the brodalumab 210 mg group, 27.0 percent of patients in the brodalumab 140 mg group, 18.5 percent of patients in the Stelara group and 0.3 percent of patients in the placebo group achieved total clearance of skin disease (PASI 100).

In addition, 85.1 percent of patients in the brodalumab 210 mg group, 69.2 percent of patients in the brodalumab 140 mg group, 69.3 percent of patients in the Stelara group and 6.0 percent of patients in the placebo group achieved PASI 75.

"Despite a variety of treatment options available for psoriasis, many patients still do not meet skin clearance goals," said Sean Harper, executive vice president of Research and Development at Amgen. "These results are of particular importance as they are the first to demonstrate superiority to Stelara in achieving total skin clearance, and the second positive pivotal Phase 3 study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis."

The most common adverse events that occurred in the brodalumab arms (more than 5 percent of patients in either group) were common cold, joint pain, upper respiratory tract infection and headache. Serious adverse events occurred in 1.4 percent of patients in the 210 mg group and 1.6 percent of patients in the 140 mg group compared with 0.6 percent for Stelara and 1.0 percent for placebo during the placebo-controlled period.

Brodalumab is the only investigational treatment in development that binds to the interleukin-17 (IL-17) receptor and inhibits inflammatory signaling by blocking the binding of several IL-17 cytokines (A, F, A/F and C) to the receptor. The IL-17 receptor and cytokine family play a central role in development and clinical manifestation of plaque psoriasis.

Continue reading here:

Amgen Reveals Positive Data For Brodalumab In Patients With Plaque Psoriasis

Sabre developing travel services for emerging wearable technology

Posted on by

- TripCase provides flight alerts for Samsung smartwatches, Android Wear and Pebble watches

LONDON, Nov. 12, 2014 /PRNewswire/ -- Hot on the heels of showcasing its Google Glass prototype flight finder app at World Travel Market in London, global travel technology company Sabre has announced the next step in developing travel services that work across a number of wearable devices including smartwatches and Google Glass. The move reflects the company's view that wearables will have a dramatic impact on the way consumers shop for and experience travel.

Photo - http://photos.prnewswire.com/prnh/20141111/158018 Logo - http://photos.prnewswire.com/prnh/20131216/DA33636LOGO-b

TripCase, Sabre's leading travel itinerary management app, is the first travel app of its kind to integrate with the highly-anticipated Samsung Gear S smartwatch, launched 7 Nov in the UK market. The integration allows the traveller to click the notification on the watch to open the TripCase app to the relevant place on the mobile device, and will include a click-to-call feature next month. In addition, consumers using Android Wear devices and the Pebble and Pebble Steel watches can receive TripCase travel notifications directly to their wearable devices.

TripCase users wearing these smart devices will receive real-time flight alerts, gate changes and other travel information conveniently on their wrists at a time when minute counts. This initial integration lays the ground work for more advanced TripCase services to be accessible on wearable technology in the future. TripCase is on pace to manage more than 25 million trips in 2014.

"As the adoption of wearable technology grows, we want to ensure that the travel industry is ready to leverage this technology and serve travellers on the device they prefer," said John Samuel, senior vice president of Sabre Traveller Solutions. "Wearable technology is fast becoming a prominent means of customer notification and communication. We're looking to take it even further from a one-way means of communication to an interactive, on-the-go service experience," said Samuel.

Researchers expect a large proportion of the population to embrace wearable computing in the near future as evidenced by the adoption trajectory of other technology advances like the smart phone and tablets. Juniper Research forecasts that worldwide spending on wearable technology will hit 870 million this year and will reach 12 billion by 2018. Further, wearable computing is already expanding beyond the early adopters and quickly becoming more mainstream, according to International Data Corporation (IDC). The research firm estimates that more than 19 million wearable computing devices will be sold in 2014, and forecasts the global market to reach 111.9 million units in 2018.

Sabre's Google Glass prototype flight finder app was the company's first foray into testing wearable devices and operates by finding flights based on a user's simple voice command,: "Ok Glass, Find a Flight from London Heathrow to Miami in June."

"Wearable technologies such as smartwatches and heads-up devices like Google Glass will forever change the way consumers experience travel from shopping via virtual reality to voice command recommendation," continued Samuel. "Creating these full service experiences require not just smart devices but also more precise location services and smart recommendation services."

Sabre Labs, the technology incubator and research lab at Sabre, continues to explore the application of geo-location technologies and their application to wearable devices in the travel experience. Understanding a traveller's precise indoor location and developing services that use that context to share information and interactions on wearables will be a critical piece in creating a more intuitive experience for travellers.

Read more from the original source:

Sabre developing travel services for emerging wearable technology

SCIENCE & SPIRITUALITY, DR J P AGARWAL, MANAV DHARAM SANDESH, TALK SHOW EPISODE 1 (Ii) – Video

Posted on by


SCIENCE SPIRITUALITY, DR J P AGARWAL, MANAV DHARAM SANDESH, TALK SHOW EPISODE 1 (Ii)
Talk Show , Episode 1 Part II, live webcast by Golivewithus.com on 26th October 2014. at 10.30 AM to 11.30 AM. Dr. J P Agarwal answering questions on Science and Spirituality in Nepali, Hindi...

By: JAIPRAKASH AGARWAL

Link:

SCIENCE & SPIRITUALITY, DR J P AGARWAL, MANAV DHARAM SANDESH, TALK SHOW EPISODE 1 (Ii) - Video

Airlock of the orbital space station Mir (part of the "Kvant-2" module) – Video

Posted on by


Airlock of the orbital space station Mir (part of the "Kvant-2" module)
Moscow Memorial Museum of Cosmonautics. Airlock of the orbital space station Mir. Special pressurized compartment of the orbital station which was an integrated part of the "Kvant-2" module.This...

By: Oleg Tarabanov

The rest is here:

Airlock of the orbital space station Mir (part of the "Kvant-2" module) - Video

28.5.2014 – Take-off for the International Space Station ISS – Video

Posted on by


28.5.2014 - Take-off for the International Space Station ISS
http://www.hohenstein.com/spacetex On 28.05.2014, the German ESA astronaut Dr. Alexander Gerst set off from the cosmodrome in Baikonur/Kazakhstan on a Soyuz rocket bound for the International Space ...

By: HohensteinInstitute

Follow this link:

28.5.2014 - Take-off for the International Space Station ISS - Video